FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

0.5

hours per response:

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SCHIFF ANDREW N</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ ACRS ]								Relationship of the contract o	able)	ig Pers	on(s) to Issu 10% Ov			
	,	ERAPEUTICS, I	(Middle)		03.	3. Date of Earliest Transaction (Month/Day/Year) 03/02/2020  4. If Amendment, Date of Original Filed (Month/Day/Year)						6. 11	Officer (give title below)  Other (specify below)  Individual or Joint/Group Filing (Check Applicable						
(Street) WAYNE (City)		tate)	19087 (Zip)	. Doni	-	ative Securities Acquired, Disposed of, or Benefi								X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1 Title of 9	Socurity (Incl		DIE I - NO	1-Deriv			2A. Deer		quirea,	DIS	1	-		5. Amour	nt of	6 Ow	nership 7	7. Nature of	
			Date (Month/Day/Year)		ear)	Execution Date, if any (Month/Day/Year)		Transaction Code (Instr.					Securitie Beneficia Owned F	s illy ollowing	Form:	Direct I Indirect I str. 4)	Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reported Transacti (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock 03/				03/0	2/202	2/2020		М		8,876	A	(1)	8,8	376		D			
Common Stock															634,455		I	By Aisling Capital IV LP <sup>(2)</sup>	
			Table II -								osed of, onvertib			Owned				^	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Date,	4. Transa Code (I 8)		Derivative		6. Date Exercis Expiration Date (Month/Day/Yea		Amount of		of S g e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		Transacti (Instr. 4)	ion(S)			
Restricted stock units	(1)	03/02/2020			A		8,876		(3)		(3)	Common Stock	8,876	\$0.00 8,87		6	D		
Restricted	(1)	03/02/2020			M			8,876	(3)		(3)	Common	8,876 \$0.00 0			D			

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 2. The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest
- 3. The shares underlying these restricted stock units vest immediately.

## Remarks:

/s/ Mark Ballantyne, Attorneyin-fact

03/04/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.